Although January might not be the most promising month for harvesting, our CRC at least was able to reap their fruits of their labour, as seen in three new publications published this month.
A02 publications:
1. The study led by Lou Staudt (NCI, Bethesda) and co-authored by Julius Enssle (CRC1530 clinician scientist) employed single-cell RNA and ATAC sequencing of 103 DLBCL biopsies, which defined malignant B-cell–specific genetic subtype signatures and subclonal programs that reveal distinct differentiation states, regulatory networks, and REL-driven blocks in memory B-cell maturation, independently shaping tumor biology and patient survival after chemotherapy.
2. This study, spearheaded by Ariana Jacobs and a manifestation of the longstanding collaboration between Lou Staudt, Sebastian Scheich and Thomas Oellerich (all corresponding authors), shows that RHOA regulates oncogenic B-cell receptor signaling and cytoskeletal dynamics, which are critical for aggressive lymphoma cell survival, revealing a potential therapeutic target.
C02 | C04 publication:
3. Moritz Gräf, Paul Bröckelmann, Ron Jachimowicz et al. established and thoroughly characterized a new CCND1-rearranged non-mantle cell lymphoma cell line and corresponding xenograft model to support biological studies and preclinical testing of targeted therapies.
Read the articles:
1. Wang B, Wright G, Enssle JC et al. Axes of biological variation in diffuse large B cell lymphoma. Cancer Cell (2026). Jan 15:S1535-6108(25)00549-5. doi: 10.1016/j.ccell.2025.12.015.
2. Jacobs A, Jahn D, Beringer T et al. RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma. Proc. Natl. Acad. Sci. U.S.A. (2026). 123 (5) e2534531123. doi:10.1073/pnas.2534531123.
3. Gräf CM, Reese M, Vicente-Luque A et al. Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model. Leukemia (2026). doi: 10.1038/s41375-025-02849-3.
